BCHE and Alzheimer disease: Currently, since acetylcholine levels and neurotransmitter destabilization gradually decline in AD, which seems to be related to altered memory and cognition, cholinesterase inhibitors that raise endogenous acetylcholine content have been adopted as key strategic drug therapies for the management of cognitive and behavioral symptoms in mild to moderate forms of AD [93].